Compare · LXEO vs RVMD
LXEO vs RVMD
Side-by-side comparison of Lexeo Therapeutics Inc. (LXEO) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LXEO and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $39.58B, about 107.5x LXEO ($368.3M).
- RVMD has been more active in the news (15 items in the past 4 weeks vs 12 for LXEO).
- RVMD has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Lexeo Therapeutics Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- $368.3M
- $39.58B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 12
- 15
- Recent ratings
- 11
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest LXEO
- Chief Financial Officer Tamayo Louis Edward was granted 12,000 shares and sold $20,838 worth of shares (4,641 units at $4.49), increasing direct ownership by 8% to 97,024 units (SEC Form 4) to cover taxes
- Chief Operating Officer Otero Jose Manuel sold $20,904 worth of shares (4,666 units at $4.48) and was granted 12,060 shares, increasing direct ownership by 6% to 137,482 units (SEC Form 4) (withholding obligation)
- Chief Medical Officer Bhalla Narinder Pal was granted 55,000 shares and sold $98,593 worth of shares (22,306 units at $4.42), increasing direct ownership by 66% to 82,194 units (SEC Form 4) to cover withholding tax
- Chief Executive Officer Townsend Richard Nolan was granted 67,000 shares and sold $116,243 worth of shares (25,947 units at $4.48), increasing direct ownership by 12% to 377,817 units (SEC Form 4) to satisfy withholding tax
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Altschuler Steven
- SEC Form 4 filed by Director Agger Mette Kirstine
- SEC Form 4 filed by Director Cooperstone Brenda
- SEC Form 4 filed by Director Diaz Reinaldo M
- SEC Form 4 filed by Director Tanguler Tolga
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)